NGEN:CA:TSV-NervGen Pharma Corp (CAD)

COMMON STOCK | Biotechnology |

Last Closing

USD 2.55

Change

+0.02 (+0.79)%

Market Cap

USD 0.19B

Volume

0.04M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
ARCH:CA Arch Biopartners Inc

+0.01 (+0.61%)

USD 0.11B
COV:CA Covalon Technologies Ltd.

+0.04 (+1.09%)

USD 0.08B
MIR:CA MedMira Inc

-0.01 (-11.11%)

USD 0.06B
NRX:CA NurExone Biologic Inc.

+0.01 (+1.79%)

USD 0.04B
TTI:CA Thiogenesis Therapeutics Corp.

N/A

USD 0.03B
GSD:CA Devonian Health Group Inc

N/A

USD 0.02B
KNE:CA Kane Biotech Inc

-0.01 (-7.14%)

USD 0.02B
SBM:CA Sirona Biochem Corp

-0.01 (-14.29%)

USD 0.02B
HEM:CA Hemostemix Inc

N/A

USD 8.28M
RKV:CA Rakovina Therapeutics Inc

N/A

USD 7.22M

ETFs Containing NGEN:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.56% 38% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.56% 38% F 55% F
Trailing 12 Months  
Capital Gain 34.21% 53% F 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.21% 53% F 73% C
Trailing 5 Years  
Capital Gain 91.73% 82% B 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 91.73% 82% B 76% C+
Average Annual (5 Year Horizon)  
Capital Gain 11.83% 67% D+ 61% D-
Dividend Return 11.83% 67% D+ 61% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 31.53% 83% B 74% C
Risk Adjusted Return 37.51% 83% B 83% B
Market Capitalization 0.19B 100% F 96% N/A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector